A detailed history of Cubist Systematic Strategies, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 67,002 shares of NUVB stock, worth $188,945. This represents 0.0% of its overall portfolio holdings.

Number of Shares
67,002
Holding current value
$188,945
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.3 - $3.83 $154,104 - $256,617
67,002 New
67,002 $154,000
Q1 2024

May 15, 2024

SELL
$1.46 - $3.97 $18,785 - $51,081
-12,867 Reduced 14.2%
77,737 $282,000
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.53 $71,860 - $114,528
74,855 Added 475.3%
90,604 $136,000
Q3 2023

Nov 14, 2023

BUY
$1.26 - $2.1 $19,843 - $33,072
15,749 New
15,749 $21,000
Q1 2023

May 15, 2023

SELL
$1.6 - $2.48 $14,409 - $22,334
-9,006 Reduced 20.26%
35,446 $58,000
Q4 2022

Feb 14, 2023

SELL
$1.68 - $2.5 $48,284 - $71,852
-28,741 Reduced 39.27%
44,452 $85,000
Q3 2022

Nov 14, 2022

SELL
$0.29 - $4.04 $68,974 - $960,885
-237,843 Reduced 76.47%
73,193 $164,000
Q2 2022

Aug 15, 2022

BUY
$3.24 - $5.85 $496,312 - $896,120
153,183 Added 97.04%
311,036 $1.01 Million
Q1 2022

May 16, 2022

BUY
$4.6 - $8.83 $493,405 - $947,123
107,262 Added 212.02%
157,853 $830,000
Q4 2021

Feb 14, 2022

BUY
$7.75 - $10.05 $392,049 - $508,399
50,587 Added 1264675.0%
50,591 $430,000
Q3 2021

Nov 15, 2021

SELL
$7.78 - $10.0 $240,261 - $308,820
-30,882 Reduced 99.99%
4 $0
Q2 2021

Aug 16, 2021

SELL
$9.22 - $14.48 $1.38 Million - $2.16 Million
-149,381 Reduced 82.87%
30,886 $288,000
Q1 2021

May 17, 2021

BUY
$9.0 - $14.57 $1.62 Million - $2.63 Million
180,267 New
180,267 $1.88 Million

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $613M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.